InvestorsHub Logo
Followers 129
Posts 2150
Boards Moderated 1
Alias Born 12/27/2007

Re: None

Friday, 10/04/2019 3:46:56 PM

Friday, October 04, 2019 3:46:56 PM

Post# of 182955
ACRS= RALLYYYYYYYYYYYYY

MONSTER OPP here trading MASSIVE UNDER cash balance -Drug Approval imminent +Phase 3 data imminent :

(ACRS)--Market-Cap $42 M --Cash $115 M untill Q3 2021---2 APPROVED Drugs / Drug approval expected before mid October / second Phase 3 readout imminent for a Drug for which there is NO FDA approved rx treatment (first P3 data was strong) ---/New Partner Deal(s) also expected during Q4 = MEGA Rebound Gem with 1000% Upside potential

Actively Seeking a Commercialization Partner for RHOFADE® (oxymetazoline hydrochloride) cream, 1%

Aclaris will also seek strategic partners for ESKATA® (hydrogen peroxide) topical solution, 40% (w/w).

Aclaris is actively seeking a strategic partner to commercialize its drug candidate A-101 45% Topical Solution, an investigational compound being developed as a potential treatment for verruca vulgaris (common warts). The Company’s two ongoing Phase 3 pivotal clinical trials, THWART-1 and THWART-2, in which A-101 45% Topical Solution is being evaluated as a potential treatment for common warts, are progressing as planned. Aclaris has completed enrollment of more than 1,000 patients across these two trials, and data from both trials are expected in the second half of 2019.

Aclaris is actively seeking a development and commercialization partner for its drug candidates, ATI-501 (oral) and ATI-502 (topical), which are investigational Janus Kinase (JAK) 1/3 inhibitor compounds for the potential treatment of alopecia.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.